Acadia Pharmaceuticals' Rebranding and AI Integration
Acadia Pharmaceuticals' CEO, Catherine Owen Adams, discusses the company's recent rebranding, expansion into rare disease marketing, and the role of AI in its strategy.
As a neurological biotech, Acadia Pharmaceuticals has rolled out a rebrand to expand further into the rare disease space, with AI playing a major role in its marketing strategy.
MM+M spoke with Acadia CEO Catherine Owen Adams on the company's recent rebrand, its expansion into rare disease and how it's using AI throughout commercialization and marketing.
Adams shares her insights on the benefits and challenges of marketing as a smaller biotech and how her marketing background is helping to steer the company into 2026.
Author's summary: Acadia Pharmaceuticals rebrands and integrates AI.